ABOUT THIS EPISODE
Among patients with symptomatic nonobstructive hypertrophic cardiomyopathy (HCM), treatment with aficamten resulted in significantly greater improvements in exercise capacity and quality of life compared with placebo over 36 weeks. The ACACIA-HCM findings offer promising news for patients and clinicians managing this challenging condition. Importantly, the trial is the first to demonstrate clinically meaningful symptomatic and functional benefits with a therapy designed to address the root cause of the disease.
In this episode, Matthew Martinez, MD, FACC and Ahmad Masri, MD, FACC evaluate "ACACIA-HCM: Aficamten for symptomatic nonobstructive hypertrophic cardiomyopathy".
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research.
OTHER EPISODES IN THIS PODCAST
Nonobstructive hypertrophic cardiomyopathy (HCM) represents one of the greatest areas of unmet need in HCM management. A key question is identifying the primary driver of symptoms in these patients, as many experience significant functional limitations despite the absence of left ventricular outflo…
The future of cardiovascular health depends on prevention that begins early in life. This episode reviews strategies for recognizing cardiovascular risk at an early stage and implementing interventions that can alter the trajectory of atherosclerotic cardiovascular disease before complications occu…
Cardiovascular protection during cancer treatment is critical to help prevent complications such as heart failure. Patients should be educated on risk factors, symptom awareness, and heart-healthy behaviors. Oncologists should incorporate cardiovascular risk assessment and surveillance into treatme…
Randomized trials in stable ischemic heart disease (SIHD) show revascularization does not reduce death or myocardial infarction versus guideline-directed medical therapy, with benefit limited to symptom relief. This likely reflects lesion–ischemia mismatch, unclear ischemia origin, effective modern…
The VESALIUS-CV trial demonstrated that the PCSK9 inhibitor evolocumab significantly reduced the risk of a first major cardiovascular event in patients with diabetes who had no known significant atherosclerosis. These findings challenge current clinical practice, where PCSK9 inhibitors are typicall…
Disclaimer: The podcast and artwork embedded on this page are from American College of Cardiology, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
